Ocular Therapeutix (FRA:0OT) Short-Term Capital Lease Obligation : €1.42 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Short-Term Capital Lease Obligation?

Ocular Therapeutix's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.42 Mil.

Ocular Therapeutix's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 (€1.76 Mil) to Dec. 2023 (€1.45 Mil) and declined from Dec. 2023 (€1.45 Mil) to Mar. 2024 (€1.42 Mil).

Ocular Therapeutix's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€1.44 Mil) to Dec. 2022 (€1.51 Mil) but then declined from Dec. 2022 (€1.51 Mil) to Dec. 2023 (€1.45 Mil).

Ocular Therapeutix Short-Term Capital Lease Obligation Historical Data

The historical data trend for Ocular Therapeutix's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Short-Term Capital Lease Obligation Chart

Ocular Therapeutix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.01

1.12

1.44

1.51

1.45

Ocular Therapeutix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.70	1.58	1.76	1.45	1.42

Ocular Therapeutix Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Ocular Therapeutix Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocular Therapeutix (FRA:0OT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (FRA:0OT) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

OCUL:USA 0OT:Germany

Address

24 Crosby Drive, Bedford, MA, USA, 01730

Website

https://www.ocutx.com

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix (FRA:0OT) Headlines

No Headlines